Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Cash Flows (Unaudited)

v3.22.1
Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Operating activities      
Net loss - including non-controlling interest $ (221,962) $ (183,173) $ (876,054)
Adjustments to reconcile net loss to net cash used in operations      
Amortization of debt discount 4,558 2,835  
Accreted interest on note receivable (3,308) (7,206)  
Depreciation expense 40  
Net loss from equity method investment 5,541  
Unrealized loss on available - for - sale securities 131,535 5,500  
Changes in operating assets and liabilities      
Accounts receivable – related party (22,500)  
Interest receivable (4,216) (1,989)  
Accounts payable and accrued expenses 66,078 5,501  
Accounts payable and accrued expenses - related party 30,000 30,000  
Accumulated losses on unconsolidated investees in excess of investment 613 21,006  
Net cash used in operating activities (13,661) (127,486) (56,896)
Investing activities      
Notes receivable (119,000)  
Net cash used in investing activities (119,000)  
Financing activities      
Proceeds from short term advances, related parties 248,500  
Net cash provided by financing activities 248,500  
Net (decrease) increase in cash (13,661) 2,014  
Cash and cash equivalents - beginning of period 227,558 5,632 5,632
Cash and cash equivalents - end of period 213,897 7,646 $ 227,558
Supplemental disclosure of cash flow information      
Cash paid for interest  
Cash paid for income tax  
Supplemental disclosure of non-cash investing and financing activities      
Investment at fair value received from issuance of note receivable $ 43,000